Different effects of neuroprotectants FK-506 and cyclosporin A on susceptibility to pilocarpine-induced seizures in rats with brain injured at different developmental stages

Epilepsy Research

Volumn 61, Issue 1-3, 2004, Pages 63-72

  Setkowicz, Zuzanna ^a   Ciarach, Małgorzata ^a   Guzik, Rafal X ^a   Janeczko, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Developing brain; Mechanical injury; Neuroprotection; Pilocarpine model of epilepsy; Seizure susceptibility

Indexed keywords

CYCLOSPORIN A; PILOCARPINE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEVELOPMENT; BRAIN INJURY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; HEMISPHERE; MALE; MORTALITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SURVIVAL; SYMPTOMATOLOGY;

AGING; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN INJURIES; CONVULSANTS; CYCLOSPORINE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; NEUROPROTECTIVE AGENTS; PILOCARPINE; RATS; RATS, WISTAR; SEIZURES; TACROLIMUS;

EID: 4644295779     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2004.06.001     Document Type: Article

References (47)

1. Acarin L., Gonzalez B., Castellano B. Glial activation in the immature rat brain: implication of inflammatory transcription factors and cytokine expression. Prog. Brain Res. 132:2001;375-389
2. Albensi B.C., Sullivan P.G., Thompson M.B., Scheff S.W., Mattson M.P. Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp. Neurol. 162:2000;385-389
3. Attur M.G., Patel R., Thakker G., Vyas P., Levartovsky D., Patel P., Naqvi S., Raza R., Patel K., Abramson D., Bruno G., Abramson S.B., Amin A.R. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, cyclooxygenase-2 and PGE2 production. Inflamm. Res. 49:2000;20-26
4. Avramut M., Zeevi A., Achim C.L. The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Dev. Brain Res. 132:2001;151-157
5. Bargallo N., Burrel M., Berenguer J., Cofan F., Bunesch L., Mercader J.M. Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. AJNR Am. J. Neuroradiol. 21:2000;479-484
6. Bartynski W.S., Zeigler Z M.P., Lin L., Shadduck R.K., Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am. J. Neuroradiol. 22:2001;1901-1914
7. Carlen P.L., Skinner F., Zhang L., Naus C., Kushnir M., Perez-Velazquez J.L. The role of gap junctions in seizures. Brain Res. Rev. 32:2000;235-241
8. Castilho R.F., Hansson O., Brundin P. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. Exp. Neurol. 164:2000;94-101
9. David-Neto E., Lemos F.B., Furusawa E.A., Schwartzman B.S., Cavalcante J.S., Yagyu E.M., Romano P., Ianhez L.E. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J. Am. Soc. Nephrol. 11:2000;343-349
10. Fonseca C.G., Green C.R., Nicholson L.F. Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. Brain Res. 929:2002;105-116
11. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap A.P., Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 18:1998;5151-5159
12. Furuichi Y., Katsuta K., Maeda M., Ueyama N., Moriguchi A., Matsuoka N., Goto T., Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 965:2003;137-145
13. Goto S., Hirano A. Calcineurin in the postnatal striatum of the rat: an immunohistochemical study. Exp. Brain Res. 77:1989;442-446
14. Horner P.J., Gage F.H. Regenerating the damaged central nervous system. Nature. 407:2000;963-970
15. Jacobs K.M., Graber K.D., Kharazia V.N., Parada I., Prince D. Postlesional epilepsy: the ultimate brain plasticity. Epilepsia. 41(Suppl. 6):2000;S153-S161
16. Janeczko K. The proliferative response of astrocytes to injury in neonatal rat brain: a combined immunocytochemical and autoradiographic study. Brain Res. 456:1988;280-285
17. Janeczko K. Spatiotemporal patterns of the astroglial proliferation in rat brain injured at the postmitotic stage of postnatal development: a combined immunocytochemical and autoradiographic study. Brain Res. 485:1989;236-243
18. Janeczko K. Age-dependent changes in the proliferative response of S-100 protein-positive glial cells to injury in the rat brain. Int. J. Dev. Neurosci. 12:1994;431-440
19. Kuroda S., Janelidze S., Siesjo B.K. The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. Brain Res. 835:1999;148-153
20. Kutlay S., Savas S., Yalcin P., Ataman S., Ergin S. Central nervous system toxicity of cyclosporin A treatment in rheumatoid arthritis. Br. J. Rheumatol. 36:1997;397-399
21. Leker R.R., Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res. Rev. 39:2002;55-73
22. Li P.A., Kristian T., He Q.P., Siesjo B.K. Cyclosporin A enhances survival, ameliorates brain damage, and prevents secondary mitochondrial dysfunction after a 30-min period of transient cerebral ischemia. Exp. Neurol. 165:2000;153-163
23. Lortie A., Plouin P., Chiron C., Delalande O., Dulac O. Characteristics of epilepsy in focal cortical dysplasia in infancy. Epilepsy Res. 51:2002;133-145
24. Mathieson P.W. Cyclosporin: nefro-protective as well as nefrotoxic? Clin. Exp. Immunol. 121:2000;179-180
25. Matsuura K., Kabuto H., Makino H., Ogawa N. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res. 733:1996;101-104
26. Maxwell W.L., Follows R., Ashhurst D.E., Berry M. The response of the cerebral hemisphere of the rat to injury. I. The mature rat. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 328:1990;479-500
27. Maxwell W.L., Follows R., Ashhurst D.E., Berry M. The response of the cerebral hemisphere of the rat to injury. II. The neonatal rat. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 328:1990;501-513
28. Miyata K., Omori N., Uchino H., Yamaguchi T., Isshiki A., Shibasaki F. Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia. Neuroscience. 105:2001;571-578
29. Okonkwo D.O., Povlinshock J.T. An intrathecal bolus of cyclosporin A before injury preseres mitochodrial integrity and attenuates axonal disruption in traumatic brain injury. J. Cereb. Blood Flow Metab. 19:1999;443-451
30. Polli J.W., Billingsley M.L., Kincaid R.L. Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Brain Res. Dev. Brain Res. 63:1991;105-119
31. Priel M.R., dos Santos N.F., Cavalheiro E.A. Developmental aspects of the pilocarpine model of epilepsy. Epilepsy Res. 26:1996;115-121
32. Prince D.A., Tseng G.F. Epileptogenesis in chronically injured cortex: in vitro studies. J. Neurophysiol. 69:1993;1276-1291
33. Przepiorka D., Blamble D., Hilsenbeck S., Danielson M., Krance R., Chan K.W. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 26:2000;601-605
34. Rice D., Barone S. Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspect. 108(Suppl. 3):2000;405-408
35. Santos J.B., Schauwecker P.E. Protection provided by cyclosporin A against excitotoxic neuronal death is genotype dependent. Epilepsia. 44:2003;995-1002
36. Scheff S.W., Sullivan P.G. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J. Neurotrauma. 16:1999;783-792
37. Setkowicz Z., Janeczko K. Long-term changes in susceptibility to pilocarpine induced status epilepticus following neocortical injuries in the rat at different developmental stages. Epilepsy Res. 53:2003;216-224
38. Setkowicz Z., Klak K., Janeczko K. Long-term changes in postnatal susceptibility to pilocarpine-induced seizures in rats exposed to gamma radiation at different stages of prenatal development. Epilepsia. 44:2003;1267-1273
39. Siesjo B.K., Siesjo P. Mechanisms of secondary brain injury. Eur. J. Anaesthesiol. 13:1996;247-268
40. Snyder S.H., Sabatini D.M., Lai M.M., Steiner J.P., Hamilton G.S., Suzdak P.D. Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 19:1998;21-26
41. Sullivan P.G., Thompson M.B., Scheff S.W. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp. Neurol. 160:1999;226-234
42. Sullivan P.G., Thompson M., Scheff S.W. Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp. Neurol. 161:2000;631-637
43. Uchino H., Minamikawa-Tachino R., Kristian T., Perkins G., Narazaki M., Siesjo B.K., Shibasaki F. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol. Dis. 10:2002;219-233
44. Wakita H., Tomimoto H., Akiguchi I., Kimura J. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke. 26:1995;1415-1422
45. Wong M., Yamada K. Developmental characteristics of epileptiform activity in immature rat neocortex: a comparison of four in vitro seizure models. Dev. Brain Res. 128:2001;113-120
46. Yoshimoto T., Siesjo B.K. Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia. Brain Res. 839:1999;283-291
47. Yoshimoto T., Uchino H., He Q.P., Li P.A., Siesjo B.K. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. Brain Res. 899:2001;148-158